Menu

To set up a press or media interview with this expert contact:

Charles Margulis

Email: charles.margulis@phi.org
Cell: 510-560-3657

Biography

Anne Kelsey Lamb, MPH, is the Director of Regional Asthma Management and Prevention (RAMP), a project of the Public Health Institute. Serving as the Director since 2002, Ms. Lamb provides overall strategic guidance in working toward the organization’s vision and mission, ensuring a highly effective organization and innovative, successful programs. Emphasizing both prevention and management, Ms. Lamb leads RAMP in building capacity, creating linkages, and mobilizing networks to advance policy and systems change targeting the root causes of asthma disparities. Through both government and foundation grants, RAMP works to: advance comprehensive policies on housing quality, affordability and tenant protections; shape policies to reduce air pollution in inequitably burdened communities; and increase access to prevention-oriented services within health care, and advance workforce development for asthma professionals.

Prior to leading RAMP, Ms. Lamb worked at Kaiser Permanente, the National Tay-Sachs & Allied Diseases Association, the Massachusetts Department of Public Health Genetics Program, and the Prevention Center of Boston. Ms. Lamb received a Master’s degree in Public Health from the University of Michigan.

Work With Us

You change the world. We do the rest. Explore fiscal sponsorship at PHI.

Bring Your Work to PHI

Support Us

Together, we can accelerate our response to public health’s most critical issues.

Donate

Find Employment

Begin your career at the Public Health Institute.

See Jobs

Close

Breakthrough Infection Study of Over 600,000 Veterans Shows Declining COVID-19 Vaccine Protection

A new pre-print study of over 600,000 veterans by researchers from PHI and the Veterans Affairs Medical Center finds that overall COVID-19 vaccine protection declined significantly between February and August 2021. Declines were greatest for the Johnson & Johnson vaccine (from 88% in March to 3% in August), followed by PfizerBioNTech (91% to 50%) and Moderna (92% to 64%).

More

Continue to PHI.org